Sutro Biopharma (NASDAQ:STRO) has been given a $18.00 price target by research analysts at HC Wainwright in a research note issued on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 84.62% from the company’s previous close.
A number of other research analysts also recently weighed in on STRO. Zacks Investment Research downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Cowen reiterated a “buy” rating on shares of Sutro Biopharma in a research note on Thursday. Wedbush increased their price target on shares of Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Finally, ValuEngine upgraded shares of Sutro Biopharma from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $22.75.
Sutro Biopharma stock traded down $0.41 during mid-day trading on Friday, reaching $9.75. The company’s stock had a trading volume of 16,700 shares, compared to its average volume of 22,826. The company has a market cap of $232.69 million and a P/E ratio of -1.59. Sutro Biopharma has a 12 month low of $8.50 and a 12 month high of $15.90.
Hedge funds have recently made changes to their positions in the business. American International Group Inc. acquired a new stake in Sutro Biopharma in the fourth quarter valued at $38,000. Deutsche Bank AG acquired a new stake in Sutro Biopharma in the fourth quarter valued at $87,000. Spark Investment Management LLC acquired a new stake in Sutro Biopharma in the first quarter valued at $168,000. SG Americas Securities LLC acquired a new stake in Sutro Biopharma in the fourth quarter valued at $169,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Sutro Biopharma in the first quarter valued at $496,000. Hedge funds and other institutional investors own 47.43% of the company’s stock.
About Sutro Biopharma
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
See Also: What is a Tariff?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.